Last reviewed · How we verify

Taurolidine Urokinase

Universitair Ziekenhuis Brussel · Phase 3 active Small molecule

Taurolidine urokinase works by combining the antimicrobial properties of taurolidine with the fibrinolytic properties of urokinase to treat infections and promote wound healing.

Taurolidine urokinase works by combining the antimicrobial properties of taurolidine with the fibrinolytic properties of urokinase to treat infections and promote wound healing. Used for Treatment of catheter-related bloodstream infections.

At a glance

Generic nameTaurolidine Urokinase
Also known asTaurolock Urokinase 25,000
SponsorUniversitair Ziekenhuis Brussel
Drug classAntimicrobial
ModalitySmall molecule
Therapeutic areaInfectious Diseases
PhasePhase 3

Mechanism of action

Taurolidine has antimicrobial properties that help to reduce bacterial load, while urokinase has fibrinolytic properties that help to break down blood clots and promote wound healing. This combination makes taurolidine urokinase effective in treating infections and promoting wound healing.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: